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A straightforward synthesis of (S)- and (R)-N-Boc-5-oxo-
piperazine-2-carboxylic acid, is reported starting from L- or 
D-serine and ethyl glyoxylate. Those were evaluated as 
constituents in two tetrapeptides by studying their 
secondary structure by 1H-NMR spectroscopy. In the case 
of Boc-Val-(S)-PCA-Gly-Leu-OMe, two readily 
interconverting conformations (in a 40:60 % ratio) were 
observed, differing for the cis-trans isomerizaton of the 
tertiary amide bond, while, Boc-Val-(R)-PCA-Gly-Leu-
OMe, displayed an equilibrium between a γ-turn and a type 
II β-turn conformation. 
 
The design and synthesis of conformationally restricted 
amino acids has been the focus of extensive research, because 
these compounds mimic or induce specific secondary 
structural features of peptides and proteins.1 Since the 
discovery of the crucial role of proline in protein structures, 
cyclic α-amino acids containing a heterocyclic ring have 
attracted considerable attention both from synthetic and 
medicinal chemists.2 In particular several six-membered ring 
heterocyclic amino acids have been synthesized, comprising 
derivatives of pipecolic,3 piperazine-2-carboxylic,4  1,4-
thiazine-3-carboxylic,5 1,3-thiazine-4-carboxylic6 and 
morpholine-3-carboxylic acid.7 5-Oxo-piperazine-2-carboxylic 
acid (PCA, Figure 1), on the other hand, has received much 
less attention, and only few reports deal with its synthesis, 
structural and biological properties.8 
In the frame of our studies directed towards the synthesis of 
peptidomimetics with well defined conformational properties,9 
we became interested in the synthesis of 5-oxo-piperazinone-
2-carboxylic acid (PCA), and its introduction into peptide 
sequences as an inducer of secondary structures. 
Herein we report a practical synthesis of (S)- and (R)-N-
Boc-5-oxo-piperazine-2-carboxylic acid 1 (Figure 1), its 
introduction into peptides by a solution-phase peptide-
synthesis strategy, and a conformational analysis of two 
tetrapeptide mimics incorporating a PCA residue. 
N
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Figure 1. (S)-N-Boc-5-oxo-piperazine-2-carboxylic acid 1. 
 
Our synthetic approach (Scheme 1) started from L-serine 
methyl ester hydrochloride which was N-alkylated using ethyl 
glyoxylate in the presence of Pd/C and under an atmosphere of 
H2. Following a procedure that has been reported for the 
synthesis of 2,3-diamino propionic acid starting from serine 
derivatives,10 the resulting alcohol 2 was transformed into the 
azide 3 by a Mitsunobu reaction using a solution of hydrazoic 
acid in toluene. Other methodologies involving the activation 
of the hydroxyl group of serine were hampered by a 
concurrent elimination reaction leading to the corresponding 
dehydroalanine derivative as the major reaction product.  
 
Scheme 1. Synthesis of (S)-N-Boc-5-oxo-piperazine-2-carboxylic acid 
1. 
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Catalytic hydrogenation of 3 with Pd/C caused reduction of 
the azide to the primary amine with concurrent cyclization to 
methyl 5-oxo-piperazinone-2-carboxylate 4 in quantitative 
yield. Finally, a one pot hydrolysis of the methyl ester and N-
Boc protection afforded N-Boc-5-oxo-piperazine-2-carboxylic 
acid 1 in pure form. The synthesis of (R)-1 was analogously 
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achieved starting from D-serine. The protection of the amino 
group of methyl (S)-5-oxo-piperazinone-2-carboxylate 4 was 
then realized using FmocCl in a biphasic aqueous NaHCO3 
dioxane medium in good yield. (S)-N-Fmoc-5-oxo-piperazine-
2-carboxylic acid methyl ester 5 could be crystallized from a 
mixture of methanol and diethylether to allow an X-ray 
structure analysis: the piperazinone ring adopts a half-chair 
conformation with the methoxycarbonyl group in a pseudo-
axial and the N-protecting group in an equatorial orientation. 
This arrangement, which has been reported for pipecolic acid 
containing peptides,11 was found also in solution as judged by 
the coupling constants for the protons on C2/C3 being smaller 
than 5 Hz (typically 4.4  Hz). The amide group displays a 
planar geometry as expected with the N-H bond bisecting the 
angle of the vicinal CH2 group. 
 
 
Figure 2. X-ray structure of methyl (S)-N-Fmoc-5-oxo-piperazine-2-
carboxylate 5. 
 
To evaluate the enantiomeric purity of these derivatives, 
(S)-1 and (R)-1 were then coupled to (R)-1-
phenylethylamine.7,12 The coupling was achieved in good yield 
using EDC (N-ethyl,N’-[3’-(dimethylamino)propyl] 
carbodiimide) / HOBT (1-hydroxybenzotriazole) / iPr2NEt, 
however, the optical purity of the resulting N-Boc amides 
could not be established neither by HPLC nor by NMR, the 
latter being complicated by doubling of the signals due to 
rotamers caused by the N-Boc group. Removal of the Boc 
protecting group revealed a single set of NMR signals, 
whereas HPLC analysis of the single amides and of the 1:1 
mixture showed that in both (S)-1 and (R)-1 cases the amides 
were obtained with a d.e. greater than 95%. 
The ability of both (S)- and (R)-PCA to act as proline 
mimics in inducing turn structures when inserted into peptide 
sequences, was then studied. Two tetrapeptide sequences: 
Boc-Val-(S)-PCA-Gly-Leu-OMe 6 and Boc-Val-(R)-PCA-
Gly-Leu-OMe, 7 were prepared by solution phase peptide 
synthesis (Boc strategy) using HATU (O-(7-azobenzotriazol-
1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate) to 
couple Boc-PCA to the Gly-Leu-OMe dipeptide and Boc-Val 
to the PCA moiety. Similar sequences containing L- or D-
proline,13 and other proline mimics among which (S)- (R)-
pipecolic acid11 have been studied and their preferred 
conformations in solutions were determined by 1H-NMR. In 
the latter case both thermodynamic and kinetic aspects of the 
cis-trans isomerization about pipecolic peptide bonds have 
been studied.  
A conformational study of 6 and 7 was performed in CDCl3 
solution by 1H-NMR. In the case of Boc-Val-(S)-PCA-Gly-
Leu-OMe 6, the 1H-NMR spectrum (5 mM) showed two sets 
of signals in a 1.7 : 1 ratio, which were attributed to the trans 
and cis tertiary amide isomers, respectively (37 % of the cis-
conformer). It has been reported that the presence of a 
pipecolic acid residue leads to a significant increase in 
population of the cis conformer (35-50%),11 whereas the cis 
amide-content in tetrapeptides containing L-proline appears to 
be definitely lower (up to 21% if an aromatic amino acid, Phe 
or Tyr, is preceeding proline in the sequence).14 Analogously, 
the introduction of a morpholine-3-carboxylic acid (Mor) in 
the tetrapeptide sequence Ac-Val-(S)-Mor-Gly-Leu-OMe 
resulted in a 2:3 mixture of cis and trans rotamers (40 % of 
the cis-conformer) at the Val-Mor amide bond.7b NOESY 
experiments conducted at 298 K revealed the presence of 
intense exchange cross peaks (EXSY) between the cis and 
trans PCA containing peptides, which hampered the correct 
attribution of the signals to the cis and trans conformers. This 
is indicative of a rather low barrier to isomerization, as can 
also be inferred from the coalescence of several backbone 
(and amide) signals, which is observed by heating the sample 
to 313 K. The presence of pipecolic acid ring is reported to 
increase the kinetics of cis-trans isomerizaton with respect to 
proline, but with PCA an even faster isomerization is 
observed. When a NOESY experiment was conduced at 273 K 
the exchange peaks were far less intense and contacts for the 
two conformers could be assigned. The trans conformer did 
not show the presence of relevant cross-peaks indicative of a 
well organized structure. This fact, together with the relatively 
low chemical shift value of the NH signals (δ ≤ 7.0 ppm) and 
their high temperature coefficients (see the Supporting 
Information for the 1H-NMR spectra and the determination of 
the ∆δ/∆T values), is indicative of a random coil structure. In 
the case of the cis-conformer (Figure 3), the Gly-NH appears 
at a remarkably deshielded chemical shift value (δ = 8.27 
ppm) and with a temperature coefficient indicative of an 
equilibrium between an intramolecularly bonded and a non-
bonded status. The NOESY experiments showed a rather 
strong contact between Val H-α and H-2 of the PCA moiety, 
indicating both the cis-conformation of the amide bond and 
the presence of a β-turn structure stabilized by a 10-membered 
cyclic hydrogen bond. 
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Figure 3. Hypothesized conformation of tetrapeptide Boc-Val-(S)-
PCA-Gly-Leu-OMe 6: the arrow indicates the NOE contact between 
Val H-α and H-2 of the PCA moiety. 
 
The 1H-NMR spectrum of the heterochiral Boc-Val-(R)-
PCA-Gly-Leu-OMe (7) showed a single set of signals 
indicating the existence of a single rotamer in solution, which, 
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owing to a strong NOE contact between the Val H-α and the 
H-6 protons of the PCA residue, was assigned to the trans 
isomer. A study of the chemical shift of the amide protons and 
their temperature coefficients determination (Table 1) 
indicated for Gly-NH an equilibrium between hydrogen-
bonded and nonhydrogen-bonded states; a similar behavior 
could be assumed for Leu-NH, although with a distinctively 
lower chemical shift.  
 
Table 1. 1H-NMR chemical shifts at rt and temperature coefficients 
for tetrapeptide 7. 
NH δ (ppm) ∆δ/∆T (ppb/K) 
Val-NH 5.13 -1.82 
PCA-NH 6.38 -10.25 
Gly-NH 7.79 -4.59 
Leu-NH 6.53 -2.78 
 
The NOESY experiments showed strong contacts of Gly 
NH with H-2 and on H-6 of the PCA moiety as well as with 
Leu-NH. These findings are consistent with an equilibrium 
between a γ-turn and a type II β-turn conformations (Figure 4).  
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Figure 4. Hydrogen-bonded structures for tetrapeptide Boc-Val-(R)-
PCA-Gly-Leu-OMe 7: the arrows indicate significant NOE contacts. 
 
A 1H-NMR study in DMSO-d6 revealed, two sets of signals 
in a 1.7 : 1 ratio, which were attributed to the trans and cis 
tertiary amide isomers, respectively. The NOESY experiment 
showed intense exchange peaks and the absence of significant 
long range interactions. This behavior is in agreement with 
other similar cases.13,15 
Conformational preferences of compounds 6 and 7 were 
investigated by Monte Carlo simulations without imposing 
any constraint, using Spartan 06 version 1.03. The lowest 
energy conformations calculated substantially reflect the 
experimentally observed structures (see the Supporting 
Information for a more detailed description of these results). 
In conclusion we have reported a straightforward synthesis 
of both (S)- and (R)-N-Boc-5-oxo-piperazine-2-carboxylic 
acid 1, starting from serine and ethyl glyoxylate. The 
incorporation of both enantiomeric tertiary amino acids into a 
model tetrapeptide was obtained by solution phase peptide 
synthesis and their turn inducing abilities studied by 1H-NMR 
spectroscopy. Interestingly Boc-Val-(S)-PCA-Gly-Leu-OMe 6, 
showed two readily interconverting conformations (in a 40:60 
% ratio), differing in the cis and trans configuration of the 
tertiary amide bond. The barrier to isomerization of the tertiary 
amide is unusually low with a coalescence temperature of 313 
K. On the other hand, Boc-Val-(R)-PCA-Gly-Leu-OMe 7, 
which contains the R-PCA enantiomer showed a more defined 
turn conformation. 
 
Experimental Section 
 
(S)-2-(Ethoxycarbonylmethyl-amino)-3-
hydroxypropionic acid methyl ester (2). L-serine methyl 
ester hydrochloride (1.0 g, 6.45 mmol) was dissolved in 
methanol, then triethylamine (902 µL, 6.48 mmol), a 50% 
solution of ethyl glyoxalate in toluene, and 10% Pd/C (90 mg), 
were successively added, and the resulting mixture was stirred 
overnight under a hydrogen atmosphere. The suspension was 
filtered over a pad of Celite, and the solvent was removed 
under reduced pressure. The crude product was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH, 98:2) to 
afford the desired product as a colorless oil (902 mg, 68%). 
[α]20D  -27.8 (c 1.0, CHCl3); 1H NMR (CDCl3) δ 4.21-4.15 (q, 
2H, J = 8.7 Hz), 3.79 (dd, 1H, J1 = 11.1 Hz, J2 = 4.5 Hz), 3.75 
(s, 3H), 3.69 (dd, 1H, J1 = 5.8 Hz, J2 = 11.1 Hz), 3.52 (d, 1H, J 
= 17.4 Hz), 3.40 (d, 1H, J = 17.5 Hz), 2.76 (br, 1H), 1.26 (t, 
3H, J = 7.1 Hz). 13C NMR δ 172.5, 172.0, 62.4, 62.3, 61.1, 
52.3, 48.9, 14.1. IR (nujol) νmax 3329, 3184, 1723, 1377, 1201, 
1068; Anal calcd for C8H15NO5: C 46.82%, H 7.37%, N 
6.83% Found: C 46,74%, H 7,32%, N 6,46%.  
(S)-3-Azido-2-(ethoxycarbonylmethyl-amino)-propionic 
acid methyl ester (3). Triphenylphosphine (1.44 g, 5.50 
mmol) was added to a solution of 2 (807 mg, 3.93 mmol) in 
dry toluene 30.0 mL under nitrogen at room temperature. 
After complete dissolution of the phosphine, HN3 (0.5 M in 
toluene) (15.70 mL, 7,86 mmol) was added, followed by 
diisopropylazodicarboxylate (DIAD, 1.10 mL, 5.50 mmol). 
After 2 hours the mixture was directly purified by flash 
chromatography (CH2Cl2/MeOH, 99:1) to give the desired 
product as a colorless oil (796 mg, 88%). [α]20D -37.6 (c 0.5, 
CHCl3); 1H NMR (CDCl3) δ 4.19 (q, 2H, J = 7.1 Hz), 3.77 (s, 
3H), 3.58-3.56 (m, 2H), 3.52-3.46 (m, 3H), 2.33 (br, 1H), 1.25 
(t, 3H, J = 7,1 Hz); 13C NMR (CDCl3) δ 171.9, 171.5, 60.9, 
60.2, 53.0, 52.3, 49.0, 14.1; IR (CH2Cl2) νmax 3352, 3063, 
2108, 1744, 1445; HRMS (ESI+) m/z calcd for 
[C8H14N4NaO4]+ 253.O9073 [M+Na]+ found 253.09097 
(S)-5-Oxo-piperazine-2-carboxylic acid methyl ester (4). 
Pd/C (0.112 mmol 0.1 eq) was added to a solution of 3 (260 
mg, 1.12 mmol) in MeOH (5 mL). The reaction was stirred 
overnight at rt under 1.0 atm of H2. The solution medium was 
then filtrated through a pad of celite and the solvent was 
evaporated under reduced pressure. The crude was purified by 
flash chromatography (DCM/MeOH, 92:8) to obtain the 
desired product as a white paste (176 mg, 99%). [α]20D -46.3 (c 
1.0, CHCl3); 1H NMR (CDCl3) δ 6.87 (br, 1H), 3.77 (s, 3H), 
3.75 (dd, 1H, J1 = 8,0 Hz, J2 = 4,4 Hz), 3.66 (d, 1H, J = 17.1 
Hz), 3.61 (ddd, 1H, J1 = 11,8 Hz, J2 = 4,4 Hz, J3 = 3.1 Hz), 
3.53 (d, 1H, J = 17.4 Hz), 3.52 (ddd, 1H, J1 = 11,8 Hz, J2 = 
8,0 Hz, J3 = 1.8 Hz), 2.15 (br, 1H); 13C NMR (CDCl3) δ 171.3, 
169.8, 54.3, 53.0, 48.3, 44.2; IR (CH2Cl2) νmax 3406, 3354, 
3211, 1744, 1678; HRMS (EI) m/z calcd for [C6H10N2O3]+ 
158.06910 [M]+ found 158.06920 
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(S)-5-Oxopiperazine-1,2-dicarboxylic acid 1-tert-butyl 
ester (1). Compound 4 (120 mg, 0.76 mmol) was dissolved in 
a 1:1 dioxane/NaOH (1.0 M) solution (2.0 mL) at rt. The 
mixture was cooled to 0°C and Boc2O (331 mg, 1.52 mmol) 
was added. After 15 minutes the ice bath was removed and the 
reaction was stirred for 10 h at rt. The reaction was quenched 
by addition of water 5.0 mL, and the aqueous phase was 
washed with EtOAc (2 x 3.0 mL). The aqueous solution was 
acidified until pH = 3 mediating addition of a 1.0 M solution 
of KHSO4. The acid phase was extracted with EtOAc (5 x 5.0 
mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and after purification by flash 
chromatography (CH2Cl2/MeOH, 97:3) the product (S)-1 was 
collected as a white powder (163 mg, 88%). Mp 103-104 °C; 
[α]20D -33.8 (c 0.5, CH3OH); Two sets of signals were 
observed in the 1H and 13C NMR spectrum due to the presence 
of two rotational isomers A:B (2:1 ratio) 1H NMR (CDCl3) δ 
8.35 (d, 1HB, J = 3.2 Hz), 8.20 (d, 1HA, J = 4.0 Hz), 4.99 (d, 
1HA, J = 4,0 Hz), 4.79 (d, 1HB, J = 4.0 Hz), 4.23 (d, 1HA and 
1HB, J = 18.8 Hz), 4.07 (d, 1HA and 1HB, J = 18,8 Hz), 3.88 
(dd, 1HA, J1 = 12,6 Hz, J2 = 3.9 Hz), 3.84 (dd, 1HB, J1 = 17.3 
Hz, J2 = 4.1 Hz), 3.65 (dd, 1HA and 1HB, J1 = 17.3 Hz, J2 = 
4.9 Hz), 1.50 (s, 9HA), 1.48 (s, 9HB); 13C NMR (CDCl3) δ 
174.3 (A), 174.0 (B), 170.7 (A), 170.1 (B), 154.4 (A), 153.6 
(B), 81.9 (A), 81.8 (B), 52.6 (A), 51.1 (B), 45.9 (A), 45.3 (B), 
42.4 (A), 40.7 (B), 28.3 (A), 28.2 (B); IR (CH2Cl2) νmax 3408, 
3230, 1707, 1647; HRMS (ESI+) m/z calcd for [C10H16N2O5]+ 
244.1059 [M+H]+ found 244.1060 
(S)-5-Oxopiperazine-1,2-dicarboxylic acid 1-(fluoren-9-
yl) ester 2-methyl ester (5). 4 (128 mg, 0.81 mmol) was 
dissolved in a 2:1 water:dioxane (3.0 mL) solution and 
NaHCO3 (136 mg, 1.61mmol) was added. The mixture was 
cooled to 0°C and a solution of Fmoc-Cl (209 mg, 0.81 mmol) 
in dioxane (1.5 mL) was added dropwise over 15 min. The ice 
bath was removed and the reaction mixture was left stirring 
for 2.5 h at rt. Successively, the mixture was partitioned 
between EtOAc 14.0 mL and water 7.0 mL, and the organic 
phase was washed with 1.0 M HCl and brine and dried over 
Na2SO4. The organic solvent was removed and the crude 
product was purified by flash chromatography (DCM/MeOH, 
95:5) to afford desired compound 5 (258 mg, 87%). Mp 143-
144 °C; [α]20D -11.9 (c 1.0, CHCl3); two sets of signals were 
observed in the 1H and 13C NMR spectrum due to the presence 
of two rotational isomers A:B (3:1 ratio)1H NMR (CDCl3) δ 
6.57 (bs,1HB), 6,54 (bs, 1HA), 5,04 (t, 1HA, J = 2.0 Hz), 4.61 
(bs, 1HB),4.60-4.49 (m, HA and HB), 4.44 (dd, 1HA, J1 = 7.2 
Hz, J2 = 3.6 Hz), 4.28-4.15 (m, 2HA and 1HB), 4.12 (d, 1HA, J 
= 18.0 Hz), 4.03 (d, 1HB, J = 18.4 Hz) 3.84 (dd, 1HB, J1 = 5.2 
Hz, J2 = 1.6 Hz), 3.81 (dd, 1HB, J1 = 3.6 Hz, J2 = 1.6 Hz), 3.78 
(s, 3HA), 3.71 (s, 3HB), 3.68 (dd, 1HA, J1 = 13.2 Hz, J2 = 4.8 
Hz), 3.57 (dd, 1HA, J1 = 12.8 Hz, J2 = 4.4 Hz); 13C NMR 
(CDCl3) δ 169.7(A), 169.6(B), 167.4(B), 166.9(A), 155.2(A), 
154.3(B), 143.6 (A and B), 143.5(B), 143.4(A), 141.4(A and 
B), 141.3(A and B), 127.92(A), 127.88(B), 127.82(B), 
127.22(A), 127.20(A), 127.15(B), 127.1(B), 124.9(A), 
124.7(B), 124.6(B), 120.1(A), 120.0(B), 68.4(A), 67.8(B), 
53.1(A and B), 52.5(B), 52.0(A), 47.2(B), 47.1(A), 46.0(A 
and B), 42.3(A and B); IR (nujol) νmax 3195, 1745, 1694, 
1410, 1315, 1232, 1099; Anal calcd for C21H20N2O5: C 
66.29%, H 5.30%, N 7.37%. Found C 66,20%, H 5,35%, N 
7,28%.  
X-Ray crystallographic data of 5: C21H20N2O5 ; MW = 
380.39 g.mol-1; T = 123 K; λ (Mo Kα) = 1.54184 A; 
Orthorhombic, space group P 21 21 21, a = 6.5176(2) A, b = 
11.6690(5) A, c = 23.9190(9) A, α = 90°,.β = 90°, γ = 90°, V 
= 1819.13(12) A3, ρcalc = 1.389 mg.m-3, Z = 4; 
µ(Μο, Κα) = 0.828 mm-1, R1 0.0283, wR2 0.0713, for 2679 
unique data collected in the 3.70-66.5° θ range.    
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